

Validation of Early Prognostic Data  
for Recovery Outcomes after Stroke for  
Future, Higher Yield Trials:  
A Biomarker Validation Study



# Virtual Investigator Meeting Agenda

1. **Introductions & Goals** (Steve Cramer & Cathy Stinear)
2. **Study Updates & Protocol** (Pooja Khatri)
3. **Behavioral Measures** (Steve Cramer)
4. **TMS** (Cathy Stinear)
5. **Imaging** (Brady Williamson)
6. **Safety Reporting** (Lisa Mundo & Kalli Beasley)
7. **Informed Consent Overview** (April Williams)
8. **Q & A/Discussion** (All)
9. **Closing Remarks** (All)

# Meeting Goals

- Provide study updates
- Review the protocol
- Review start up procedures
- Answer your questions

Walk you through how to enroll

Get you set up for release  
to enroll in June!

We will fine-tune the MOPP  
based on your feedback and insights

**\*Sites should complete their independent virtual trainings  
by end of May 2022\***

# VERIFY Leadership Team

## **Principal Investigators:**

Pooja Khatri, MD, MSc  
Professor of Neurology  
University of Cincinnati

Steven Cramer, MD, MMSc  
Professor of Neurology  
University of California, Los Angeles

Cathy Stinear, PhD  
Professor of Medicine  
University of Auckland, New Zealand

Achala Vagal, MD, MS  
Professor of Radiology  
University of Cincinnati

## **Primary Study Statisticians at Medical University of South Carolina:**

Lydia Foster, MS  
Sharon Yeatts PhD

## **Project Manager:**

K. Lisa Mundo, MA  
University of Cincinnati



# VERIFY Leadership Team, Continued

## **NIH StrokeNet National Coordinating Center (NCC) at University of Cincinnati**

Joseph Broderick, MD  
NCC PI for VERIFY  
Professor of Neurology  
University of Cincinnati

Laura Benken, MBA, CCRP  
NCC Administrative Co-Director

Kalli Beasley, MPH  
NCC Project Manager

## **NIH StrokeNet National Data Management Center (NDMC) at Medical University of South Carolina**

Catherine Dillon, MS  
NDMC PI for VERIFY

## **NINDS Project Scientist**

Robin Conwit, MD



# Introduction – Our VERIFY Site Teams Cont'd

Site	PI	Primary Study Coordinator
Baystate Medical Center, Springfield, MA	Gottfried Schlaug, MD, PhD	Sirisha Nouduri
Duke University Hospital, Durham, NC	Wayne Feng, MD	Randy Smith
Emory University	Michael Borich, PT, PhD	Susan Murphy
Harborview Medical Center, Seattle, WA	Nicole Mazwi, MD	Allison Kunze
Houston Methodist Hospital, Houston, TX	David Chiu, MD	David McCane
Lahey Hospital & Medical Center, Burlington, MA	Siddharth Sehgal, MD	Penhleakhena Ou
Massachusetts General Hospital, Boston, MA	David J. Lin, MD	Julie DiCarlo
Medical University of South Carolina (MUSC)	Kirstin Heise, PhD	Valerie Salisbury
MedStar Washington Hospital Center, Washington, DC	Matt Edwardson, MD	Jamal Smith
Montefiore Medical Center, Bronx, NY	Cynthia Hung, MD	Sandeep Yerra
NYU Langone Medical Center - Tisch Hospital, New York, NY	Heidi Schambra, MD	Lina Demis
OSU Wexner Medical Center, Columbus, OH	Yousef Hannawi, MD	Luke Herren
Penn State Hershey Medical Center, Hershey, PA	Raymond Reichwein, MD	TBD
Pennsylvania Hospital, Philadelphia, PA	Lawrence Wechsler, MD	Nichole Gallatti


# Introduction – Our VERIFY Site Teams Cont'd

Site	PI	Primary Study Coordinator
Ronald Reagan UCLA Medical Center, Los Angeles, CA	Jason Hinman, MD, PhD	Cristina Teran
San Francisco General Hospital	Cathra Halabi, MD	Dominica Randazzo
UF Health Shands Hospital, Gainesville, FL	Gabriel Bonnell, MD	Franklin Eschevarria
University of Alabama Hospital, Birmingham, AL	Toby Gropen, MD	Tammy Davis
University of Cincinnati Medical Center, Cincinnati, OH	Pierce Boyne, PT, PhD	Erin Wagner
University of Iowa Hospitals & Clinics, Iowa City, IA	Hannah Roeder, MD, MPH	Heena Olalde
University of Maryland Medical Center, Baltimore, MD	Robynne Braun, MD, PhD	Bisola Amodu
University of Michigan University Hospital, Ann Arbor, MI	Chandramouli Krishnan, PT, PhD	Courtney Wolf
University of Utah Healthcare, Salt Lake City, UT	Lorie Richards, OT, PhD & Jennifer Majersik, MD, MS	TBD
University of Wisconsin University Hospital, Madison, WI	Azam S. Ahmed, MD	TBD
UCSF Medical Center, San Francisco, CA	Cathra Halabi, MD	Dominica Randazzo
UPMC Presbyterian Hospital, Pittsburgh, PA	George Wittenberg, MD, PhD	Jason Weimer
UT Houston (Memorial Hermann Texas Medical Center)	Sean Savitz, MD	Emily Stevens
UT Southwestern Medical Center, Dallas, TX	Nneka L. Ifejika MD, MPH	Maddie Euckert
UVA Medical Center, Charlottesville, VA	Chad Aldridge, PT	Sonya Gunter

# Study Update and Protocol Overview



# VERIFY Video



Available in  
both  
English  
& Spanish



# VERIFY Websites

- Patient-Facing:  
<https://theverifystudy.com>  
(includes study videos)

- Study Team-Facing:  
<https://www.nihstrokenet.org/verify/home> (includes newsletters & webinars)



Home

Study Videos

List of Participant Sites

## VERIFY

Welcome to the VERIFY Study!

Validation of Early Prognostic Data for Recovery Outcome after Stroke for Future, Higher Yield Trials (VERIFY)

**Information about the study**

Stroke is a leading cause of disability that affects people in many different ways. Arm weakness is common after stroke and can greatly interfere with a person's daily life. When a stroke first happens, it's useful to know how much someone will recover, especially for the arm. Currently, however, recovery is hard to predict.

The VERIFY Study will find out whether we can use tests done early after stroke to predict a person's arm recovery during the months that follow a stroke.

Why would we want to predict arm recovery? During the months after a stroke, some people recover all the way, some people don't recover at all, and many people have a partial recovery. If we can predict how a person will do in the coming months, we can choose the right rehabilitation therapies more quickly and more accurately. And if we know what lies in the months ahead, we can plan better.

Previous research studies have found several tests that might help doctors and therapists predict arm recovery. This study will see whether these tests are useful predictors in a larger group of people.

Please consider taking part if you or a loved one has had a stroke in recent days, and they have been admitted to one of the hospitals taking part in the VERIFY study.

A person who is in the VERIFY Study will have some testing done within the first week of stroke (while they are still in the hospital), then a phone call 1 month after stroke, then a clinic visit 3 months after stroke. There is no charge to be in the study, and participants receive \$150 for their time and up to \$40 for study-related travel costs.

Any questions are best directed to personnel running the VERIFY study at each hospital. General questions can be sent to [verifystudy@ucmail.uc.edu](mailto:verifystudy@ucmail.uc.edu)

VERIFY



NIH StrokeNet  
PREVENTION | TREATMENT | RECOVERY  
Funded by a Grant from the National Institutes of Health

Home Clinical Trials Education The Network Contact Us

## VERIFY

Home Resources Webinars

Validation of Early Prognostic Data for Recovery Outcome after Stroke for Future, Higher Yield Trials (VERIFY)

**Summary:**

VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. The central hypothesis is that patients have different UE outcomes depending on corticomotor system (CMS) function, measured as motor evoked potential (MEP) status with TMS, and on CMS structure, measured as acute lesion load with MRI. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, TMS, and MRI measures in the acute stroke time window.

# VERIFY Websites Cont'd

- Clinical Trial Data Management System (<https://webdcu.musc.edu>)




WebDCU™  
Data → Information → Knowledge



CREST-2  
StrokeNet  
defuse3  
Sleep SMART  
ASPIRE  
SATURN  
VERIFY  
CAPTIVA


WebDCU™ © Copyright 2009-2022 Medical University of South Carolina. All rights reserved.



WebDCU™  
Data → Information → Knowledge



VERIFY

Pooja KHATRI Sign Out 

Help

Randomized 0% (0 / 657) of recruitment target.

Site Management Project Setup User Management Regulatory Document Toolbox Emergency Help

Full Expanded Menu

WebDCU™ © Copyright 2009-2022 Medical University of South Carolina. All rights reserved.



# Objective

- Primary: To validate the most promising biomarkers of motor recovery after ischemic stroke in this first large-scale, prospective, generalizable dataset.
  - 557 ischemic stroke patients
- Exploratory: To explore these biomarkers in a convenience sample of concurrently collected patients with intracerebral hemorrhagic stroke, for whom preliminary data are very limited.
  - 100 intracerebral hemorrhagic stroke (convenience sample)

# Primary Aims

- **Primary Aim 1:** To externally validate the relationships that TMS and MRI biomarkers of CMS integrity acquired  $\leq 7$  days after stroke have with UE motor impairment outcome at 90 days after ischemic stroke.
  - Motor impairment outcome = UE Fugl-Meyer (FM) scale score
- **Primary Aim 2:** To externally validate the PREP2 prediction tool used  $\leq 7$  days after stroke to predict 90-day UE functional outcome for individual patients with ischemic stroke.
  - Motor functional outcome = Action Research Arm Test (ARAT) score.

# Exploratory Aims

- **Exploratory Aims:** To derive and internally validate multivariable prediction tools, using TMS and MRI biomarkers as well as baseline clinical factors, to predict 90-day patient reported UE use and global functional outcome in individual patients.
  - Upper extremity use = Motor Activity Log (MAL) score
  - Global functional outcome = modified Rankin Scale [mRS] score
- **Exploratory Cohort:** Aims will also be explored in a convenience sample of 100 patients with intracerebral hemorrhage

# Deliverables

- Immediately allow reliable prediction of patient outcomes after ischemic stroke to improve stratification and inform entry criteria in clinical trials
- Enable personalized rehabilitation therapy in the long term

# Inclusion Criteria

- Age **18 years** or older
- **Unilateral** stroke due to ischemia or intracerebral hemorrhage
- **Motor deficits** in the acutely affected UE (SAFE score  $\leq 8$ ) within 48 to 96 hours of stroke onset (or time last known well).
  - **SAFE  $\leq 8$  excludes full or nearly full motor strength in both shoulder abduction and finger extension**
- Consent signed within **48 to 96 hours** of stroke onset (or LKW)
- Stated **willingness to comply** with all study procedures and available for duration
- Fluent in **English or Spanish**

# Exclusion Criteria

- **UE injury or conditions** on paretic side that limited use prior to the stroke  
*Significant functional limitation with examples noted in MOPP*
- **Legally blind**
- **Dense sensory loss** on paretic side indicated by a score of 2 on NIHSS sensory item
- Unable to abduct the shoulder or extend the fingers of the **non-paretic UE** on verbal command
- Isolated **cerebellar** stroke
- **Bilateral** acute strokes

# Exclusion Criteria Cont'd

- Co-enrollment in a trial of an **intervention targeting the incident stroke** (acute treatment or rehabilitation/recovery intervention) after baseline assessments for VERIFY are initiated

TRIAL	Concept	Considerations	Ok to Co-Enroll?	Plan approved by both trials' PIs
ARCADIA	Apixiban for stroke prevention in setting of atrial cardiopathy	Does not target acute stroke treatment or recovery	YES	X
ARCADIA-CSI	Cognitive (annual phone battery [20 min] administered centrally annually) and MRI at baseline and final visit.	Both observational; limited overlap in cognitive timing	YES	X
ASPIRE	Apixiban for stroke prevention after ICH in setting of atrial fibrillation	Does not target acute stroke treatment or recovery; only annual cognitive assessment	Yes	X
CAPTIVA	ASA with clopidogrel vs ticagrelor vs rivaroxaban for stroke prevention in ICAD	CAPTIVA Team prefers not to co-enroll due to overall study burden of CAPTIVA	NO	X
DISCOVERY	Observational study to understand mechanisms of post stroke cognitive disability	DISCOVERY Team prefers not to co-enroll due to overall study burden of DISCOVERY	NO	X
FASTEST	Factor VIIa for treatment of ICH	Does not target acute stroke treatment or recovery; <b>If Patient is enrolled via EFIC, patient should only be approached after patient is fully informed of FASTEST.</b>	YES	X
MOST	Argatroban/eptifibatide for treatment of ischemic stroke	Acute stroke treatment completed by 48 hours. <b>Patient should not be approached by VERIFY until after MOST consent experience survey on Day 3.</b>	YES	X
SATURN	Statin discontinuation in setting of ICH to prevent ICH recurrence	Study drug targets acute stroke recovery	NO	X
SATURN-MRI	Follow up MRI for SATURN trial	Study drug targets acute stroke recovery	NO	X
SLEEP-SMART	Early CPAP treatment of OSA for stroke prevention and recovery	Study intervention targets acute stroke recovery	NO	X
TRANSPORT-2	Transcranial direct stimulation for motor recovery	Limited overlap at 2-3 months from onset of stroke. <b>If co-enrollment planned, then Transport2 enrollment must occur at 3-6 months.</b>	YES	X

# Exclusion Criteria Cont'd

- Known **inability to follow up** through 90 days
- **Major medical, neurological, or psychiatric condition** that would substantially affect functional status

*Examples (end stage cancer, untreated bipolar, moderate to severe neurodegenerative disease) noted in MOPP*

- Cognitive or communication impairment **precluding informed consent** by the participant.

*Suggested comprehension questions noted in MOPP*

- Non-cerebrovascular diagnosis associated with **unlikely survival at 90 days**
- **Pregnancy**

# Exclusion Criteria Cont'd

- **Contraindication to noncontrast MRI** (certain metallic implants, metallic foreign bodies or severe claustrophobia)
- **Contraindication to TMS**
  - Cardiac pacemaker or other electronic devices in the body at or above the level of the seventh cervical vertebra (such as cochlear implant, cortical stimulator, deep brain stimulator, vagus nerve stimulator, cervical spine epidural stimulator, or ventriculoperitoneal shunt)
  - Skull defect related to current stroke
  - Seizure after onset of current stroke
  - Seizure within the last 12 months while taking anti-epileptic medications
  - Previous serious adverse reaction to TMS

# Exclusion Criteria Cont'd

- Unable to perform **behavioral assessments within 48-120 hours** of symptom onset (or time last known well).
- Unable to receive **TMS or get MRI within 72-168 hours** of symptom onset (or time last known well).
- **Anticipated instability** to perform study procedures within 168 hours of symptom onset.

# Study Schema

**HOUR 0 = STROKE ONSET (OR TIME LAST KNOWN WELL)**

**Visit 1:**  
Hour 48-96




**\*Visit 2:**  
Hour 48-120



**\*Visit 3:**  
Hour 72-168


*\*Can occur on same day*



# Study Schema

**HOUR 0 = STROKE ONSET (OR TIME LAST KNOWN WELL)**


**Visit 1:**  
Hour 48-96



**\*Visit 2:**  
Hour 48-120



**\*Visit 3:**  
Hour 72-168




*\*Can occur on same day*

# Study Schema

**HOUR 0 = STROKE ONSET (OR TIME LAST KNOWN WELL)**


**Visit 1:**  
Hour 48-96



**\*Visit 2:**  
Hour 48-120



**\*Visit 3:**  
Hour 72-168



*\*Can occur on same day*

# Study Schema Continued

## **Visit 4:**


Discharge Day $\pm$ 1  
or Post-TMS Day 5 $\pm$ 1,  
Whichever is Sooner

## **Visit 5:**

Day 30 $\pm$ 7

## **Visit 6:**

Day 90 $\pm$ 14



# Screening/Consent Workflow

## 1. Daily Chart Screening

- Identify all stroke patients (ischemic and ICH) in EMR with the following:
  - <36 hours of onset at admission
  - Some upper extremity weakness
  - Alert and able to consent themselves
  - No TMS & MRI contraindications
- Above subset of pts eligible based on full eligibility criteria?
  - NO → enter in screen failure CRF
  - YES → proceed to next step

## 2. Ask clinical team physician for the following:

- Confirm that patient has “some” weakness in shoulder abduction and/or finger extension?
  - NO → enter in screen failure CRF
  - YES → proceed to next step
- Mention study and ask if study team may approach
  - NO → enter in screen failure CRF
  - YES → proceed to next step

## 3. Patient consents?

- NO → enter in screen failure CRF
- YES → proceed to next step

## 4. SAFE score $\leq 8$ ?

- NO → enter in screen failure CRF
- YES → proceed to next step

## 5. Remains eligible until 1<sup>st</sup> TMS stimulation or start of study-specific MRI?

- NO → enter in screen failure CRF
- YES → participant is now enrolled!



# E-Consent Overview

- REDCap is a **mature, secure web application** for building and managing online surveys and databases.
- Facilitates **presentation of an electronic Informed Consent Document (eICD)** and capturing the **patient's signature**.
- To access and complete the eICD, the patient must have access to a **smartphone, tablet or computer** with Wi-Fi or cellular internet connectivity.
- Individuals provide a **handwritten signature** by using a computer mouse, or by using their finger on a cell phone or tablet touchscreen.
- REDCap **automatically saves** the signed eICD on its secure server and maintains an **audit trail** that logs all user actions.

# E-Consent Process

1. Each site will be assigned a **static URL** to share with the patient.

<https://redcap.research.cchmc.org/surveys/?s=4YKLJC7AYY>

Resize font:  Enable speech 

## CONSENT TO PARTICIPATE IN A RESEARCH STUDY

**Study Title:** Multi-arm Optimization of Stroke Thrombolysis (**MOST** Stroke Trial)

**Sponsor/Protocol Principal Investigator:** Opeolu Adeoye, MD - University of Cincinnati; James Grotta, MD - Memorial Hermann Hospital

**Performance Site Principal Investigator:** Stacie Demel, DO

**Performance Site:** University of Cincinnati Medical Center/UC Health and UC Physicians Offices and Clinics

**IRB #:** 2018-1464C-014

**Approved:** 12/11/2019

**Do Not Use After:** 12/10/2020

**Version:** 4.0

### INTRODUCTION

If you are being asked to give permission for someone else to be in this study, you should try to determine whether that person would want to be in the study. "You" throughout this form refers to that person.

You are having a stroke caused by a clot blocking blood flow to the brain. The standard treatments to remove or dissolve blockages causing stroke are helpful within the first few hours of a stroke. You are already being treated with the clot busting medicine tPA (also called alteplase) which is the main treatment. Even with tPA treatment, however, the blood vessels sometimes block up again when tPA wears off. This can worsen the stroke. This study is designed to find out whether adding one of two blood-thinning medicines helps keep blood vessels open and decrease the impact of the stroke.

# E-Consent Process

1. Each site will be assigned a static URL to share with the patient.

<https://redcap.research.cchmc.org/surveys/?s=4YKLJC7AYY>

2. The person obtaining consent will review the eICD and **provide instructions** on completing the form.

The screenshot shows a web-based consent form. At the top right, there are controls for 'Resize font' and 'Enable speech'. The main title is 'CONSENT TO PARTICIPATE IN A RESEARCH STUDY'. Below this, the study title is 'Multi-arm Optimization of Stroke Thrombolysis (MOST Stroke Trial)'. The form is divided into sections: 'Sponsor/Protocol Principal Investigator' (Hermann Hospital), 'Performance Site Principal Investigator' (University of Virginia), 'IRB #', 'Approved' date, 'Do Not Use After' date, and 'Version'. The 'INTRODUCTION' section begins with 'If you are being...' and 'You are having...'. The form contains several questions with radio button options and text input fields. Each question is marked as a required field with a red asterisk and the text '\* must provide value'. A 'reset' button is located to the right of each question. The questions are: 1. 'Is the patient able to give consent for himself/herself to participate in the study?' with options 'Yes' and 'No/Using Legally Authorized Representative'. 2. 'Are you signing this consent in person (at the hospital with study staff) or remotely?' with options 'In-person' and 'Remote/via tele-medicine'. 3. 'All of my questions have been answered, and I have been given the opportunity to decline this research.' with options 'Yes' and 'No'. 4. 'Full Name of Study Participant' with a text input field. 5. 'E-mail' with a text input field. 6. 'Phone number' with a text input field.

CONSENT TO PARTICIPATE IN A RESEARCH STUDY

Study Title: Multi-arm Optimization of Stroke Thrombolysis (MOST Stroke Trial)

Sponsor/Protocol Principal Investigator: Hermann Hospital

Performance Site Principal Investigator: University of Virginia

Performance Site: University of Virginia

IRB #: 2018-1464C-014

Approved: 12/11/2019

Do Not Use After: 12/10/2020

Version: 4.0

INTRODUCTION

If you are being...

You are having...

or dissolve blood clots...

treated with the...

treatment, how...

stroke. This stu...

blood vessels c...

Is the patient able to give consent for himself/herself to participate in the study?  Yes  No/Using Legally Authorized Representative \* must provide value reset

Are you signing this consent in person (at the hospital with study staff) or remotely?  In-person  Remote/via tele-medicine \* must provide value reset

All of my questions have been answered, and I have been given the opportunity to decline this research.  Yes  No \* must provide value reset

Full Name of Study Participant  \* must provide value

E-mail  \* must provide value

Phone number  \* must provide value

# E-Consent Process

1. Each site will be assigned a static URL to share with the patient.

<https://redcap.research.cchmc.org/surveys/?s=4YKLJC7AYY>

2. The person obtaining consent will review the eICD and provide instructions on completing the form.
3. The patient will **add their handwritten signature** (typically at bedside).

The image shows a screenshot of a web-based consent form. The main form is titled "CONSENT TO PARTICIPATE IN A RESEARCH STUDY" and includes several fields with red asterisks indicating required information. A modal window titled "Add signature" is overlaid on the form, showing a handwritten signature on a line. The modal has a "Save signature" button and a "reset" link. The background form includes fields for "Study Title", "Sponsor", "IRB #", "Approval", "Version", "E-mail", "Phone number", "Signature of Participant", and "Date". The date field shows "05-28-2020" and "Today". There are also "reset" buttons for several fields. At the top right, there are options for "Resize font" and "Enable speech".

CONSENT TO PARTICIPATE IN A RESEARCH STUDY

with study staff) or remotely?  Remote/via tele-medicine

Study Title \* must provide value

Sponsor Herman \* must provide value

Performance \* must provide value

IRB #: 2 \* must provide value

Approval Do Not \* must provide value

Version \* must provide value

E-mail \* must provide value

Phone number \* must provide value

Signature of Participant \* must provide value

Date 05-28-2020 Today

\* must provide value

Add signature

Signature of Participant

Save signature reset

# E-Consent Process

4. Upon completion of eICD, the site's **study team will receive the completed eICD PDF** via automated email.
5. The **participant** may elect to receive the eICD PDF via email.

Home Tools most\_econsent\_202... x Iris

I am not giving up any legal rights by signing this form. I will be given a copy of this signed combined consent and HIPAA research authorization form.

Is the patient able to give consent for himself/herself to participate in the study?  Yes  No/Using Legally Authorized Representative

Are you signing this consent in person (at the hospital with study staff) or remotely?  In-person  Remote/via tele-medicine

All of my questions have been answered, and I have been given the opportunity to decline this research.  Yes  No


Full Name of Study Participant John Smith

E-mail smith@uc.edu

Phone number (555) 555-5555

05/28/2020 3:21pm projectredcap.org REDCap®

*Confidential* Record ID 55 Page 4

Signature of Participant 

Date 05-28-2020

RIFY

# E-Consent Process

6. When the study team and the participant are **not in the same physical location**, which will be uncommon in VERIFY, both parties are not able to sign the eICD at the same time.


Only the participant will sign in real time and the **person obtaining consent** will subsequently complete a **remote consent attestation form**.

Statement of Informed Consent Process Using eConsent


Was this subject consented using eConsent remotely?  Yes  No  
\* must provide value reset

1. Consent was reviewed with the subject and/or LAR including, but not limited to, risks and benefits, other options for treatment, and the right to withdrawal from the study at any time without consequences.  
2. All questions were answered by the study team.  
3. Subject eligibility was confirmed per inclusion and exclusion criteria with data available at the time of consent.  
4. The subject and/or LAR consented to participate in the MOST clinical trial and signed the consent and HIPAA forms.  
5. A copy of the signed consent and HIPAA was given to the subject and/or LAR and a copy was placed in the patient chart.  
6. Proper consent process was completed prior to beginning of study procedures.

Participant Initials OR Study ID   
\* must provide value

Date of Informed Consent   Today M-D-Y

Name of Person Who Obtained Consent   
\* must provide value

Signature of Person Who Obtained Consent  [Add signature](#)  
\* must provide value

# Responsibilities

## NCC Responsibilities

- **Create** a REDCap project for each site
- Ensure that the **most recent** CIRB-approved version of the site-specific ICD is available in REDCap for eICD use.
- Provide the site with their **cIRB approval** to use the central E-Consent process and **access** to their study-specific and site-specific REDCap project.
- Maintain the **list of individuals who receive the completed eICD PDF** via automated email according to the site's DOA in WebDCU™.

## Site Responsibilities

- **Designate a primary and back-up user** to access to their REDCap E-Consent project.
- **Ensure the Remote Consent Attestation is completed**, when required, by the person who obtained consent remotely.
- Ensure the PDF versions of the eICD and Remote Consent Attestation, as applicable, are **combined into one document and uploaded to WebDCU™ within 5 days** of signature.



# Site Readiness Activities

CTA Executed and cIRB Approved



Study Staff & Investigator WebDCU Entered

- Delegation of Authority (DoA)
- Investigator Form
- TMS Shipping Address (if applicable)



TMS Machine Received (if applicable)

Online Training Done and Certifications Uploaded

- TMS
- Behavioral Assessments
- Investigators Mtg Webinar



Practical TMS Training Done

- Healthy Volunteers
- Technique check at standard sites



MRI Set Up Completed

- MRI Form Submitted
- Imaging Core Outreach Occurred & Protocol setup
- Phantom Image Approved

Study Materials Received

- Shipping Address Entered




- Materials for Participants
  - Tote Bag
  - Rehab Diary
- Materials for Behavioral Assessments

**SITE READINESS CALL  
&  
BEGIN SCREENING!!!**



# Tote Bag and Rehab Utilization Diary



# CTA and CIRB Status

29 Sites:  
 22 CTAs executed &  
 14 CIRBs approved (& 10 submitted)  
 as of Apr 22<sup>th</sup> 2022

	CTA Submitted	CTA Completed	CIRB Submitted	CIRB Completed
University of Wisconsin University Hospital				
UVA Medical Center				
MedStar Washington Hospital Center				
University of Maryland Medical Center				
The University of Utah				
University of Cincinnati Medical Center				
NYU Langone Medical Center - Tisch Hospital				
University of Texas Southwestern Medical Center				
OSU Wexner Medical Center				
UT Houston (Memorial Hermann Texas Medical Center)				
University of Alabama Hospital				
UF Health Shands Hospital				
Baystate Medical Center				
Medical University of South Carolina (MUSC)				
Montefiore Medical Center				
Emory University				
Duke University Hospital				
University of Michigan University Hospital				
San Francisco General Hospital				
UCSF Medical Center				
Harborview Medical Center				
Lahey Hospital & Medical Center				
Pennsylvania Hospital				
UPMC Presbyterian Hospital				
Massachusetts General Hospital				
Houston Methodist Hospital				
Penn State Hershey Medical Center				
Ronald Reagan UCLA Medical Center				
University of Iowa Hospitals & Clinics				

# CTA and CIRB Status

29 Sites:  
 22 CTAs executed &  
 14 CIRBs approved (& 10 submitted)  
 as Apr 22<sup>th</sup> 2022

*Who will enroll  
 the first patient???*



	CTA Submitted	CTA Completed	CIRB Submitted	CIRB Completed
University of Wisconsin University Hospital				
UVA Medical Center				
MedStar Washington Hospital Center				
University of Maryland Medical Center				
The University of Utah				
University of Cincinnati Medical Center				
NYU Langone Medical Center - Tisch Hospital				
University of Texas Southwestern Medical Center				
OSU Wexner Medical Center				
UT Houston (Memorial Hermann Texas Medical Center)				
University of Alabama Hospital				
UF Health Shands Hospital				
Baystate Medical Center				
Medical University of South Carolina (MUSC)				
Montefiore Medical Center				
Emory University				
Duke University Hospital				
University of Michigan University Hospital				
San Francisco General Hospital				
UCSF Medical Center				
Harborview Medical Center				
Lahey Hospital & Medical Center				
Pennsylvania Hospital				
UPMC Presbyterian Hospital				
Massachusetts General Hospital				
Houston Methodist Hospital				
Penn State Hershey Medical Center				
Ronald Reagan UCLA Medical Center				
University of Iowa Hospitals & Clinics				

# Staff Roles at Each Clinical Site

## **STAFF MEMBERS TO BE TRAINED AND CERTIFIED AT SITES:**

1. Site PI
2. 1<sup>0</sup> SC
3. 1<sup>0</sup> PT/OT
4. At least one additional staff member(s) and more encouraged
  - 2<sup>0</sup> SC or 2<sup>0</sup> PT/OT

Please Train **2 People** for Each Sets of Trainings:

(1) TMS (2) ARAT+FM, & (3) Other Behavioral Assessments

# Study Timeline

VERIFY Study Timeline	
September, 2021	Grant Notice of Award (NoA) received on Sept 1, 2021 and 29 sites selected
October, 2021	StrokeNet issued Clinical Trial Agreement (CTA) and central IRB packets to sites
Fall/Winter, 2021	Sites completing CTA and CIRB packets
February 28, 2022	Virtual training launch
March/April, 2022	Sites to complete virtual site trainings
April 25, 2022	Investigator meeting (virtual)
May, 2022	Complete remaining training & start up activities
June, 2022	First participant enrolled!

✓ CTA/IRB

✓ DOAs/Investigator Forms

✓ Trainings for TMS and Behavioral Assessments

✓ MRI Set Up

✓ Study Tool Shipping

✓ Site Readiness Call



# More Questions after Today?

- Contact Lisa, Kalli, PIs, or others →
- VERIFY Virtual Office Hours (optional)
  - **Weekly on Wednesdays, 2-3pm ET**
- Important Study Coordinator Webinar
  - **Tuesday, May 24<sup>th</sup>, 12pm-1pm ET**
- Monthly study coordinator/PI webinars
  - **Starting in June 2022**

## Contact Information

### **CIRB/Regulatory**

Betsy Casillo [betsy.casillo@advarra.com](mailto:betsy.casillo@advarra.com) 513.619.1679

Kalli Beasley [beasleki@ucmail.uc.edu](mailto:beasleki@ucmail.uc.edu) 513.558.2968

### **CTA/Contracts**

Wren Hansen [hansonwm@ucmail.uc.edu](mailto:hansonwm@ucmail.uc.edu) 513.558.6566

Sasha Simms [simmssc@ucmail.uc.edu](mailto:simmssc@ucmail.uc.edu) 513.558.3924

### **All Other Questions**

VERIFY Prime PM Lisa Mundo [mundokl@ucmail.uc.edu](mailto:mundokl@ucmail.uc.edu)

NCC PM Kalli Beasley [beasleki@ucmail.uc.edu](mailto:beasleki@ucmail.uc.edu)

### **VERIFY PIs:**

Pooja Khatri [khatrip@ucmail.uc.edu](mailto:khatrip@ucmail.uc.edu)

Steve C. Cramer [sccramer@mednet.ucla.edu](mailto:sccramer@mednet.ucla.edu)

Cathy Stinear [c.stinear@auckland.ac.nz](mailto:c.stinear@auckland.ac.nz)

Achala Vagal [vagala@ucmail.uc.edu](mailto:vagala@ucmail.uc.edu)



# More Questions after Today?

- Contact Lisa, Kalli, PIs, or others →
- VERIFY Virtual Office Hours (optional)
  - **Weekly on Wednesdays, 2-3pm ET**
- **Important Study Coordinator Webinar**
  - **Tuesday, May 24<sup>th</sup>, 12pm-1pm ET**
- Monthly study coordinator/PI webinars
  - **Starting in June 2022**

## Contact Information

### **CIRB/Regulatory**

Betsy Casillo [betsy.casillo@advarra.com](mailto:betsy.casillo@advarra.com) 513.619.1679

Kalli Beasley [beasleki@ucmail.uc.edu](mailto:beasleki@ucmail.uc.edu) 513.558.2968

### **CTA/Contracts**

Wren Hansen [hansonwm@ucmail.uc.edu](mailto:hansonwm@ucmail.uc.edu) 513.558.6566

Sasha Simms [simmssc@ucmail.uc.edu](mailto:simmssc@ucmail.uc.edu) 513.558.3924

### **All Other Questions**

VERIFY Prime PM Lisa Mundo [mundokl@ucmail.uc.edu](mailto:mundokl@ucmail.uc.edu)

NCC PM Kalli Beasley [beasleki@ucmail.uc.edu](mailto:beasleki@ucmail.uc.edu)

### **VERIFY PIs:**

Pooja Khatri [khatrip@ucmail.uc.edu](mailto:khatrip@ucmail.uc.edu)

Steve C. Cramer [sccramer@mednet.ucla.edu](mailto:sccramer@mednet.ucla.edu)

Cathy Stinear [c.stinear@auckland.ac.nz](mailto:c.stinear@auckland.ac.nz)

Achala Vagal [vagala@ucmail.uc.edu](mailto:vagala@ucmail.uc.edu)



# Behavioral Measures

# 7 Study Specific Behavioral Assessment Trainings

Accurate measurement of behavior is critical to correctly capturing patient outcomes and to measuring key patient characteristics.

Studies show that formal training improves the accuracy of, and reduces variability in, behavioral assessment scoring.

The VERIFY Study has 13 Specific behavioral assessments for which training, and certification are needed.

These certifications can be obtained through 7 different trainings distributed across 3 different web-based platforms.



# 7 Study Specific Behavioral Assessment Trainings

## BlueCloud

1. Upper Extremity Fugl-Meyer Scale
2. Action Research Arm Test
3. Rankin Focused Assessment

## MoCA website

4. Montreal Cognitive Assessment

## PDF Slide Deck & Survey Link

5. Behavioral Assessments Training Certification which includes the following assessments:
  1. Motor Activity Log-14 (amount of use)
  2. 10-Meter Walk Test
  3. EQ-5D (EuroQol-5D)
  4. Geriatric Depression Scale-15Q
  5. NeuroQOL-Anxiety-8Q
  6. Star Cancellation Test
  7. Pain Visual Analog Scale

## DCU Campus

6. Modified Rankin Scale
7. NIH Stroke Scale



# 7 Study Specific Behavioral Assessment Trainings

## BlueCloud

1. Upper Extremity Fugl-Meyer Scale
2. Action Research Arm Test
3. Rankin Focused Assessment

Examiners must use only use the specific versions of case report forms and specific assessment kits provided by the VERIFY Study.



## MoCA website

4. Montreal Cognitive Assessment

## PDF Slide Deck & Survey Link

5. Behavioral Assessments Training Certification which includes the following assessments:
  1. Motor Activity Log-14 (amount of use)
  2. 10-Meter Walk Test
  3. EQ-5D (EuroQol-5D)
  4. Geriatric Depression Scale-15Q
  5. NeuroQOL-Anxiety-8Q
  6. Star Cancellation Test
  7. Pain Visual Analog Scale

## DCU Campus

6. Modified Rankin Scale
7. NIH Stroke Scale



# 7 Study Specific Behavioral Assessment Trainings

## BlueCloud

1. Upper Extremity Fugl-Meyer Scale
2. Action Research Arm Test
3. Rankin Focused Assessment

## Frequency of recertification

Every 6 months

Every 6 months

Every 2 years

## MoCA website

4. Montreal Cognitive Assessment

Every 2 years

## PDF Slide Deck & Survey Link

5. Behavioral Assessments Training Certification which includes the following assessments:

Every 1 year

1. Motor Activity Log-14 (amount of use)
2. 10-Meter Walk Test
3. EQ-5D (EuroQol-5D)
4. Geriatric Depression Scale-15Q
5. NeuroQOL-Anxiety-8Q
6. Star Cancellation Test
7. Pain Visual Analog Scale

## DCU Campus

6. Modified Rankin Scale
7. NIH Stroke Scale

Every 2 years

Every 2 years



# 7 Study Specific Behavioral Assessment Trainings

## BlueCloud

1. Upper Extremity Fugl-Meyer Scale
2. Action Research Arm Test
3. Rankin Focused Assessment

## MoCA website

4. Montreal Cognitive Assessment

## PDF Slide Deck & Survey Link

5. Behavioral Assessments Training Certification which includes the following assessments:
  1. Motor Activity Log-14 (amount of use)
  2. 10-Meter Walk Test
  3. EQ-5D (EuroQol-5D)
  4. Geriatric Depression Scale-15Q
  5. NeuroQOL-Anxiety-8Q
  6. Star Cancellation Test
  7. Pain Visual Analog Scale

## DCU Campus

6. Modified Rankin Scale
7. NIH Stroke Scale

## Frequency of recertification

Every 6 months

Every 6 months

Every 2 years

Every 2 years

Every 1 year

Every 2 years

Every 2 years

- If you have recently trained and certified on a particular scale, you can upload this to WebDCU.
- Your next recertification will be according to this schedule.



# Training and certification- BlueCloud

## BlueCloud

1. Upper Extremity Fugl-Meyer Scale
2. Action Research Arm Test
3. Rankin Focused Assessment

### 1. Go to <https://secure.bluecloud.net/verify-study>

- IF ALREADY REGISTERED, CONFIRM YOUR ACCOUNT: If you previously registered at BlueCloud, confirm your personal account is active by logging in using your previously registered e-mail address.
- IF YOU ARE NOT ALREADY REGISTERED, CREATE AN ACCOUNT: If you do not have a BlueCloud account, register and create your own personal account.

2. Send an email to Dr. Cramer's lab ([cramerlab@mednet.ucla.edu](mailto:cramerlab@mednet.ucla.edu)) indicating that you have a registered BlueCloud account. Send this from the email account you used to register at BlueCloud.

3. We will assign you the 3 BlueCloud training courses and then send you an email to let you that these have been assigned. Further instructions will be provided in that email.



# Training and certification- MoCA website

## MoCA website

### 6. Montreal Cognitive Assessment

1. Go to <https://www.mocatest.org/members/register/>
2. Fill in the blanks to create an account and register.
3. Go to <https://www.mocatest.org/get-certified> to begin the certification process.
4. Towards the bottom of the page, enter **VpXa6RwYk** in the Enter Group Code box. This code is for the VERIFY study only—please do not share this code or use it in any other context.
5. Proceed with MoCA training and certification. Note that we will be using paper case report forms for MoCA testing, and not electronic MoCA testing.
6. When you have completed and passed MoCA certification, take a screen snapshot of your Certificate of Completion and then please upload it to WebDCU.



# Training and certification- PDF Slide Deck and Survey Link

## Behavioral Assessments Training Certification:

1. Motor Activity Log-14 (amount of use)
2. 10-Meter Walk Test
3. EQ-5D (EuroQol-5D)
4. Geriatric Depression Scale-15Q
5. NeuroQOL-Anxiety-8Q
6. Star Cancellation Test
7. Pain Visual Analog Scale

1. The PDF Slide Deck for the Behavioral Assessments Training Certification that incorporates these 7 scales will be provided:
  1. In the WebDCU VERIFY study toolbox <https://webdcu.musc.edu/login.asp>
  2. Via e-mail upon request from the Project Manager
2. After you finish viewing the training slides, open the URL provided on the last slide:  
<https://redcap.link/VerifyBehavioralMeasuresCertification>

# Training and certification- PDF Slide Deck and Survey Link

## Behavioral Assessments Training Certification:

1. Motor Activity Log-14 (amount of use)
2. 10-Meter Walk Test
3. EQ-5D (EuroQol-5D)
4. Geriatric Depression Scale-15Q
5. NeuroQOL-Anxiety-8Q
6. Star Cancellation Test
7. Pain Visual Analog Scale

1. The PDF Slide Deck for the Behavioral Assessments Training Certification that incorporates these 7 scales will be provided:
  1. In the WebDCU VERIFY study toolbox  
<https://webdcu.musc.edu/login.asp>
  2. Via e-mail upon request from the Project Manager
2. After you finish viewing the training slides, open the URL provided on the last slide: <https://redcap.link/VerifyBehavioralMeasuresCertification>

Resizé font: | Enable speed

# VERIFY

Welcome to the VERIFY Behavioral Measures Certification Test. This certification is to ensure responsible research conduct and participant safety.

You have 3 hours to complete this test. You are allowed to save and return to the test later. Select the answer that best fits each question. You need at least a 95% to pass this test.

Please complete the assessment below. Once completed, select the 'Next Page' button at the end of the test and follow the directions on the next page.

Thank you.

**First/Given and Last/Family Name**  
\* must provide value  As used in WebDCU Example: Jane Doe

**Date**  
\* must provide value  Today

Q01 When scoring the Motor Activity Log, the patient is instructed to answer based on their best estimate of what they think they can do, rather than based on their actual performance.  True  False reset




# Training and certification- PDF Slide Deck and Survey Link

## Behavioral Assessments Training Certification:

1. Motor Activity Log-14 (amount of use)
2. 10-Meter Walk Test
3. EQ-5D (EuroQol-5D)
4. Geriatric Depression Scale-15Q
5. NeuroQOL-Anxiety-8Q
6. Star Cancellation Test
7. Pain Visual Analog Scale

1. The PDF Slide Deck for the Behavioral Assessments Training Certification that incorporates these 7 scales will be provided:
  1. In the WebDCU VERIFY study toolbox <https://webdcu.musc.edu/login.asp>
  2. Via e-mail upon request from the Project Manager
2. After you finish viewing the training slides, open the URL provided on the last slide:  
<https://redcap.link/VerifyBehavioralMeasuresCertification>
3. Once you pass this test, you must upload a PDF of the passing notification into WebDCU. Two options:
  1. Take a screenshot of the webpage, save it as a PDF, and upload to WebDCU, OR
  2. Select the option to have the results emailed to you. Then save that email as a PDF and upload it to WebDCU



# Training and certification- PDF Slide Deck and Survey Link

## Behavioral Assessments Training Certification:

1. Motor Activity Log-14 (amount of use)
2. 10-Meter Walk Test
3. EQ-5D (EuroQol-5D)
4. Geriatric Depression Scale-15Q
5. NeuroQOL-Anxiety-8Q
6. Star Cancellation Test
7. Pain Visual Analog Scale

If you did not pass this test:

- Review the training materials, and then
- Retake the test

**NOTE:** This training will be available in the future through the DCU Training Center.

1. The PDF Slide Deck for the Behavioral Assessments Training Certification that incorporates these 7 scales will be provided:
  1. In the WebDCU VERIFY study toolbox <https://webdcu.musc.edu/login.asp>
  2. Via e-mail upon request from the Project Manager
2. After you finish viewing the training slides, open the URL provided on the last slide:  
<https://redcap.link/VerifyBehavioralMeasuresCertification>
3. Once you pass this test, you must upload a PDF of the passing notification into WebDCU. Two options:
  1. Take a screenshot of the webpage, save it as a PDF, and upload to WebDCU, OR
  2. Select the option to have the results emailed to you. Then save that email as a PDF and upload it to WebDCU



# Training and Certification- DCU Training Center

## DCU Campus

- 4. Modified Rankin Scale
- 5. NIH Stroke Scale

1. Go to <https://dcu.musc.edu/campus/>
2. Click on mRS Training Video
3. When you finish watching the video, click on mRS Certification Test. Enter your data in the Test Registration boxes and hit Submit. Take the test.
4. When you pass the mRS test, hit “Print mRS Certificate” and then save your certificate. Then please send it to your site coordinator, who will later upload it to WebDCU^^.
5. Repeat steps 2-4 for the NIH Stroke Scale.

*^^Once the site's electronic DOA log is approved by NCC, the regulatory and training document requirements will be automatically posted based on study team members' roles. The site coordinator will then upload PDFs of the training certifications in WebDCU under [People Reg Doc Submission].*



# Things we will mail to you for behavioral assessments

ARAT Kits

Rehab Diaries

2 red sharpie markers

Arm motor Fugl-Meyer test kit

- i. stopwatch (with resolution to hundredths of a second)
- ii. tennis ball
- iii. small cylinder
- iv. pencil
- v. reflex hammer

Star Cancellation Test, testing sheets (clean copies)

- i. 40 copies in English
- ii. 30 copies in Spanish
- iii. protective folder holding these copies

50-foot tape measure

1 roll of bright orange masking tape



# Things we will mail to you for behavioral assessments

ARAT Kits

Will be shipped directly to you from the manufacturer  
NeuroQuip  
London, UK

Rehab Diaries

2 red sharpie markers

Arm motor Fugl-Meyer test kit

- i. stopwatch (with resolution to hundredths of a second)
- ii. tennis ball
- iii. small cylinder
- iv. pencil
- v. reflex hammer

Star Cancellation Test, testing sheets (clean copies)

- i. 40 copies in English
- ii. 30 copies in Spanish
- iii. protective folder holding these copies

50-foot tape measure

1 roll of bright orange masking tape

# Things we will mail to you for behavioral assessments

## ARAT Kits

### Rehab Diaries

2 red sharpie markers

### Arm motor Fugl-Meyer test kit

- i. stopwatch (with resolution to hundredths of a second)
- ii. tennis ball
- iii. small cylinder
- iv. pencil
- v. reflex hammer

### Star Cancellation Test, testing sheets (clean copies)

- i. 40 copies in English
- ii. 30 copies in Spanish
- iii. protective folder holding these copies

50-foot tape measure

1 roll of bright orange masking tape

Will be shipped directly to you in a single box from  
The Cramer lab  
Los Angeles, CA

# We will also mail Rehab Diaries to you



Front cover

In each row, enter the date of therapy. Then enter number of minutes of each type of therapy.

Date	Occupational Therapy	Physical Therapy	Speech Therapy	Other (Specify)
4/11/22	45	30	50	45 Psychotherapy
4/12/22	60	60	45	
4/13/22	30	45	45	60 Recreational
4/14/22	45	50	30	50 Music
4/19/22	60	60	60	

Inside front flap

In each row, enter the date of therapy. Then enter number of minutes of each type of therapy.

Date	Occupational Therapy	Physical Therapy	Speech Therapy	Other (Specify)

1 of 30 data pages

John Smith  
VERIFY Study  
Anywhere Med Center  
(555) 555-1212

Back cover  
(you can write your name & contact info)



# Visit 6: In-person vs. Videoconference vs. Telephone

Procedures	STUDY VISIT 1 Screening & Consent Hour 48-96*	STUDY VISIT 2 Baseline Clinical Assessment Hour 48-120 <sup>a</sup>	STUDY VISIT 3 Baseline Biomarker and Clinical History Assessment (ENROLLMENT) Hour 72-168**	STUDY VISIT 4 Post-TMS Hospital Discharge Day± 1 or Post-TMS Day 5± 1, Whichever is Sooner	STUDY VISIT 5 Post-Hospitalization Phone Follow Up Day Day 30 ± 7* By Phone	STUDY VISIT 6 Post-Hospitalization In-Person Assessment Day 90± 14*
Informed consent	X					
SAFE score	X					
Demographics	X					
Pregnancy Test, if applicable	X					
UE-FM		X				X
NIHSS		X				X
MRI***			X			
TMS			X			
Medical history			X			
Rehab Utilization Assessment				X	X	X†
Pre-stroke mRS without RFA		X				X†
mRS via RFA					X	X†
ARAT						X
MAL-14						X
10-Meter Walk Test						X
EQ5D						X†
MoCA						X†
Geriatric Depression Scale						X†
NeuroQOL Anxiety (8Q)						X†
Star Cancellation Test						X
Pain Visual Analog Scale (for only shoulder of affected side)						X†
Adverse Events (AEs)			X	X		
Serious AE and AE of Special Interest			X	X	X	X†
Complete CRFs	X	X	X	X	X	X†

† If Study Visit 6 cannot occur by person, then the indicated assessments can be done by videoconference, but note that on a videoconference, EQ5D will be performed without the visual analog portion. If only phone assessment is possible, then the same tests can be performed except for the MOCA, which is skipped for a phone-based visit.



# Additional Tips for Visit 6

- Study staff should train participants not to unblind their visit 6 assessors on whether their hand moved during the TMS procedure.
- The study coordinator may perform gait testing only if the participant has already been specifically cleared to walk independently by an OT or PT.
  - Otherwise, a licensed OT or PT should assist the study coordinator with performing the gait testing to ensure participant safety.

# TMS



THE UNIVERSITY OF  
**AUCKLAND**  
Te Whare Wānanga o Tāmaki Makaurau  
NEW ZEALAND

# TMS team



Prof. Cathy Stinear

Harry Jordan

# SAFE Score and TMS Training

verifytraining.blogs.auckland.ac.nz



[SAFE Score](#)   [TMS Training](#)

## SAFE and TMS Training Homepage

### SAFE Score Training

[SAFE Score](#)

### TMS Training

[Introduction](#)

[1. TMS Overview](#)

[2. TMS Safety Checklist](#)

[3. EMG Technique](#)

[4. TMS Technique](#)

[5. Simple MEP](#)

[Identification](#)



# SAFE Score Training

Training Status: 31 people certified  
Need full spread of SAFE scores 0 - 8



Shoulder Abduction out of 5



Finger Extension out of 5

# TMS Training

Completed by TMS Operators

## **THEORY**

- Online
- Self-directed

## **PRACTICE**

- Healthy volunteers
- Technique check

Online theory training completed by 14 TMS Operators

TMS Assistants- No training but need to be on DOA

# TMS Training

	<b>Standard Track</b>
Theory complete	Yes
Practice sessions	Yes
Healthy volunteer data submitted	N = 5
Technique check	Yes

# TMS Training

	<b>Standard Track</b>	<b>Fast Track</b>
Theory complete	Yes	Yes
Practice sessions	Yes	Yes
Healthy volunteer data submitted	N = 5	N = 2
Technique check	Yes	No

# TMS Safety Checklist

Required for ALL participants

Healthy volunteers during training and technique checks

VERIFY patients

Requires physician sign-off

Only once for healthy volunteers – review before each session

Should be kept on site as evidence of completion



# Healthy volunteers

Practice the entire protocol

Consent healthy volunteers for practice sessions

\$25 per session, maximum of \$100

Submit healthy volunteer form with number of sessions completed to generate payment

After you have practiced:

Standard sites

Submit 5 datasets per operator for checking

We will arrange a technique check with you

Fast track sites

Submit 2 datasets per operator for checking



# Adverse events of special interest

TMS is considered safe and very low risk for those who pass the Safety Screening Checklist

Adverse events are very unlikely: 0.08% chance, or 8 in 10,000

Seizure – during or immediately after the TMS test

Syncope – due to procedure-related anxiety

Mild headache – usually transient and resolves without analgesia

# TMS monitoring

Required for VERIFY patients

- Throughout the TMS test by visual observation
- Note time of last stimulus and continue observing while packing up
- Observe at 15 and 30 minutes after time of last stimulus
- You are looking for involuntary or unexpected limb movements
- Medical team assumes usual care after 30 minutes

# Have a plan

Before you begin recruiting

Seizure management – medical staff who will use local protocols

Syncope and mild headache – transient and low risks of harm  
Communicate these events to the patient's medical team



# TMS Hotline

TMS Hotline available in June 2022

The number will be posted in “Emergency Help” in WebDCU

You can call or text

Monday – Friday 0800 – 2100h ET

For non-urgent questions you can email us at  
[verify.study.tms@gmail.com](mailto:verify.study.tms@gmail.com)



# SAFE Score and TMS Training

[verifytraining.blogs.auckland.ac.nz](http://verifytraining.blogs.auckland.ac.nz)

## SAFE and TMS Training Homepage



### TMS Training

0. Introduction
1. TMS Overview
2. TMS Safety Checklist
3. EMG Technique
4. TMS Technique
5. Simple MEP Identification
6. Challenging MEP Identification
7. TMS Case Report Form
8. Practical TMS Training

Resources

[MEGA-TMS Software Support](#)

[About Us](#)



# Imaging

# Imaging Team

---



**Dr. Achala Vagal; MD,MS**  
**PI, Imaging management Center**




**Sholeh Bazrafshan, MD, MS**  
**Imaging Project Manager**



**Vivek Khandwala, PhD**  
**Database Manager**



**Tyler Behymer, BS**  
**Imaging Project Manager**



**Brady J. Williamson, PhD**  
**Research Assistant Professor**



# Updates

- 21 of 29 sites completed MRI survey
- 8 sites completed their protocol setup
  - 3 more very close
- 6 sites have completed/confirmed image upload training
  - Please work with us to complete this part of the workflow ASAP! We cannot collect phantoms until someone at your site is able to successfully upload images to Ambra

	MRI Survey Received
Baystate Medical Center	
University of Michigan University Hospital	
Duke University Hospital	
University of Maryland Medical Center	
UPMC Presbyterian Hospital	
University of Cincinnati Medical Center	
University of Utah Healthcare	
Emory University	
UVA Medical Center	
University of Wisconsin University Hospital	
UF Health Shands Hospital	
Houston Methodist Hospital	
Ronald Reagan UCLA Medical Center	
NYU Langone Medical Center	
UT Houston (Memorial Hermann Texas Medical	
MedStar Washington Hospital Center	
Massachusetts General Hospital	
Medical University of South Carolina	
Lahey Hospital & Medical Center	
UT Southwestern Medical Center	
Montefiore Medical Center	
University of Iowa Hospitals & Clinics	
Pennsylvania Hospital	
UCSF Medical Center	
San Francisco General Hospital	
OSU Wexner Medical Center	
University of Alabama Hospital	
Harborview Medical Center	
Penn State Hershey Medical Center	

# Neuroimaging Protocol

- Required sequences of MRI brain for VERIFY
  - **DWI/ADC, FLAIR, T2, and GRE/SWI:** Routine clinical sequences
  - **3D-T1 MRI:** Not always routine clinical sequence
    - *High-resolution (1mm<sup>3</sup>), high-tissue contrast (BRAVO, MPRAGE) T1-weighted image*
- Three scenarios
  - #1: **All MRI sequences** above (incl 3D-T1) are completed as standard of care (SOC)  $\geq$  of onset  $\rightarrow$  **no further VERIFY imaging needed**
  - #2: **All MRI sequences except 3D-T1** are completed as SOC  $\geq$  24h of onset  $\rightarrow$  **perform 3D-T1 with DWI for VERIFY within 24-168h from onset**
  - #3: **MRI not available** as SOC (ie, not performed or performed at  $<$ 24h) from onset  $\rightarrow$  **perform full MRI for VERIFY within 24-168h from onset**
  - **NOTE: “Per patient” budget includes reimbursement for full MRI**
- If 3D-T1 not SOC, work with **Dr. Brady Williamson @ [willi3by@ucmail.uc.edu](mailto:willi3by@ucmail.uc.edu)** to set it up
- Detailed imaging manual



# What Imaging Needs to be Submitted?

- **MRI done at 24-168h** (whether acquired as SOC or study-specific)
  - DWI/ADC, FLAIR, T2, and GRE/SWI
  - 3D-T1 MRI
- **Acute neuroimaging at 0-24h** (only scans performed as SOC)
  - CT/CTA +/- CTP or MRI/MRA +/- MRP
- **Recurrent stroke imaging**
  - First choice: MRI if performed as SOC
  - Second choice: CT scan

# How to Submit Imaging?

- All imaging needs to be submitted to core lab –**imaging upload is part of payment schedule requirements**
- ***Imaging Uploading Manual*** is provided with detailed instruction
  - 1) How to Submit Imaging
  - 2) Accessing Ambra Health<sup>®</sup>
  - 3) Uploading Images into Ambra Health<sup>®</sup>

Please contact **Tyler Behymer** @ [behymetp@ucmail.uc.edu](mailto:behymetp@ucmail.uc.edu)  
with any questions.



# Best Practices Protocol Set-Up at Your Site

- Contact our team as **early** in the process as possible
- **All questions** are worth asking!
  - We do not mind the extra emails and taking time to answer any concerns you may have, so please reach out as often as needed
- Best if we can work directly with **someone in your radiology/MR dept**
  - Very important to receive your MRI questionnaire for correct contact information
- Most efficient way to achieve setup is to send us your **MRI imaging protocol export** as soon as possible from your scanner(s)
  - We can check the protocol(s) to see if study requirements are met



# Phantom Testing

- Phantom testing is **crucial** to the success of the study
  - Ensures consistency across all sites so we know data is comparable
- We only require **standard ACR phantom** that should be available at all sites
  - Typically used for regularly scheduled (daily) scanner QC
- Phantom scan needed **only for study-specific T1**, not whole protocol
  - Only takes as long as the T1 sequence (~4.5-5 minutes)
  - **Maximum 10 min of your MRI tech's time**
- **Twice per year**, starting with study startup
- Needs to be collected **with any scanner hardware/software updates** so we can quantify any deviations

**Once phantom MRI scan is approved by imaging core,  
you have completed MRI set-up!**



# FAQs for Imaging

- Q: Which specific scan parameters need to match for the sequence to meet study requirements?
  - A: Sequence type (MPRAGE or BRAVO) and resolution (1mm isotropic)
- Q: How can I ensure that the study protocol is set up?
  - A: We are asking sites to send us the protocol export from their scanner(s) to ensure that the protocol is set up properly and for our records
- Q: Do we need a human volunteer scan after protocol setup?
  - A: No, we are only collecting phantoms before the site is ready to start scanning study participants

# Questions on Imaging

---

- *Questions regarding image **protocol and acquisition**, please contact:*

**Brady Williamson, PhD**  
Research Assistant Professor  
University of Cincinnati  
Department of Radiology  
Email: [willi3by@ucmail.uc.edu](mailto:willi3by@ucmail.uc.edu)

- *Questions regarding **image upload**, please contact our imaging coordinator:*

**Tyler P. Behymer, BS**  
Sr. Clinical Research Coordinator  
University of Cincinnati College of Medicine  
Department of Radiology  
Email: [behymetp@ucmail.uc.edu](mailto:behymetp@ucmail.uc.edu)

***Note: You can also contact AMBRA customer service via the Ambra database for individual upload issues, should they arise.***

*We will work with your Radiology contact for imaging set-up including phantom scans and imaging uploads*



# Safety Reporting

# Adverse Events (AEs)

Procedures	STUDY VISIT 1 Screening & Consent Hour 48-96*	STUDY VISIT 2 Baseline Clinical Assessment Hour 48-120#	STUDY VISIT 3 Baseline Biomarker and Clinical History Assessment (ENROLLMENT) Hour 72-168**	STUDY VISIT 4 Post-TMS Hospital Discharge Day ± 1 or Post-TMS Day 5 ± 1, Whichever is Sooner	STUDY VISIT 5 Post-Hospitalization Phone Follow Up Day Day 30 ± 7* By Phone	STUDY VISIT 6 Post-Hospitalization In-Person Assessment Day 90 ± 14*
Informed consent	X					
SAFE score	X					
Demographics	X					
Pregnancy Test, if applicable	X					
UE-FM		X				X
NIHSS		X				X
MRI***			X			
TMS			X			
Medical history			X			
Rehab Utilization Assessment				X	X	X†
Pre-stroke mRS without RFA		X				
mRS via RFA					X	X†
ARAT						X
MAL-14						X
10-Meter Walk Test						X
EQ5D						X†
MoCA						X†
Geriatric Depression Scale						X†
NeuroQOL Anxiety (8Q)						X†
Star Cancellation Test						X
Pain Visual Analog Scale (for only shoulder of affected side)						X†
Adverse Events (AEs)			X	X		
Serious AE and AE of Special Interest			X	X	X	X†
Complete CRFs	X	X	X	X	X	X†

## What is an Adverse Events (AEs)?

- Any untoward medical occurrence or worsening of a preexisting medical condition in a research participant that does not necessarily have a causal relationship with the study procedures.
- AEs reported from time of enrollment (defined as having started TMS or study-specific MRI sequence) throughout initial hospitalization or up to 5 days post-TMS administration, whichever is sooner.



# Adverse Events (AEs)

Procedures	STUDY VISIT 1 Screening & Consent Hour 48-96*	STUDY VISIT 2 Baseline Clinical Assessment Hour 48-120#	STUDY VISIT 3 Baseline Biomarker and Clinical History Assessment (ENROLLMENT) Hour 72-168**	STUDY VISIT 4 Post-TMS Hospital Discharge Day ± 1 or Post-TMS Day 5 ± 1, Whichever is Sooner	STUDY VISIT 5 Post-Hospitalization Phone Follow Up Day Day30 ± 7* By Phone	STUDY VISIT 6 Post-Hospitalization In-Person Assessment Day 90 ± 14*
Informed consent	X					
SAFE score	X					
Demographics	X					
Pregnancy Test, if applicable	X					
UE-FM		X				X
NIHSS		X				X
MRI***			X			
TMS			X			
Medical history			X			
Rehab Utilization Assessment				X	X	X†
Pre-stroke mRS without RFA		X				
mRS via RFA					X	X†
ARAT						X
MAL-14						X
10-Meter Walk Test						X
EQ5D						X†
MoCA						X†
Geriatric Depression Scale						X†
NeuroQOL Anxiety (8Q)						X†
Star Cancellation Test						X
Pain Visual Analog Scale (for only shoulder of affected side)						X†
Adverse Events (AEs)			X	X		
Serious AE and AE of Special Interest			X	X	X	X†
Complete CRFs	X	X	X	X	X	X†

- Thereafter, only AEs that meet the definition of an SAE or AEs of special interest will be reported.



# AEs of Special Interest

Procedures	STUDY VISIT 1 Screening & Consent Hour 48-96*	STUDY VISIT 2 Baseline Clinical Assessment Hour 48-120#	STUDY VISIT 3 Baseline Biomarker and Clinical History Assessment (ENROLLMENT) Hour 72-168**	STUDY VISIT 4 Post-TMS Hospital Discharge Day ± 1 or Post-TMS Day 5 ± 1, Whichever is Sooner	STUDY VISIT 5 Post-Hospitalization Phone Follow Up Day Day30 ± 7* By Phone	STUDY VISIT 6 Post-Hospitalization In-Person Assessment Day 90± 14*
Informed consent	X					
SAFE score	X					
Demographics	X					
Pregnancy Test, if applicable	X					
UE-FM		X				X
NIHSS		X				X
MRI***			X			
TMS			X			
Medical history			X			
Rehab Utilization Assessment				X	X	X†
Pre-stroke mRS without RFA		X				
mRS via RFA					X	X†
ARAT						X
MAL-14						X
10-Meter Walk Test						X
EQ5D						X†
MoCA						X†
Geriatric Depression Scale						X†
NeuroQOL Anxiety (8Q)						X†
Star Cancellation Test						X
Pain Visual Analog Scale (for only shoulder of affected side)						X†
Adverse Events (AEs)			X	X		
Serious AE and AE of Special Interest			X	X	X	X†
Complete CRFs	X	X	X	X	X	X†

## What are the AEs of Special Interest?

1. Seizure, during or within 1 hour of TMS completion
2. AEs deemed by the site investigator as potentially related to study participation



# Serious Adverse Events

Procedures	STUDY VISIT 1 Screening & Consent Hour 48-96*	STUDY VISIT 2 Baseline Clinical Assessment Hour 48-120#	STUDY VISIT 3 Baseline Biomarker and Clinical History Assessment (ENROLLMENT) Hour 72-168**	STUDY VISIT 4 Post-TMS Hospital Discharge Day ± 1 or Post-TMS Day 5 ± 1, Whichever is Sooner	STUDY VISIT 5 Post-Hospitalization Phone Follow Up Day Day30 ± 7* By Phone	STUDY VISIT 6 Post-Hospitalization In-Person Assessment Day 90± 14*
Informed consent	X					
SAFE score	X					
Demographics	X					
Pregnancy Test, if applicable	X					
UE-FM		X				X
NIHSS		X				X
MRI***			X			
TMS			X			
Medical history			X			
Rehab Utilization Assessment				X	X	X†
Pre-stroke mRS without RFA		X				
mRS via RFA					X	X†
ARAT						X
MAL-14						X
10-Meter Walk Test						X
EQ5D						X†
MoCA						X†
Geriatric Depression Scale						X†
NeuroQOL Anxiety (8Q)						X†
Star Cancellation Test						X
Pain Visual Analog Scale (for only shoulder of affected side)						X†
Adverse Events (AEs)			X	X		
Serious AE and AE of Special Interest			X	X	X	X†
Complete CRFs	X	X	X	X	X	X†

## What are Serious Adverse Events (SAEs)?

- Results in death
- Is life-threatening
- Requires inpatient hospitalization or causes prolongation of existing hospitalization
- Results in persistent or significant disability/incapacity
- Is an important medical event that may jeopardize the pt or may require intervention [e.g., medical, surgical] to prevent one of the other serious outcomes listed in above.




# SAEs and AEs of Interest

Sites must report SAEs and AEs of interest in WebDCU™ within 24 hours of site awareness of the event

Relevant information must be provided:  
description of event, date/time of onset, date of resolution, severity, suspected relationship to the study procedures, and action taken

Additional supporting documentation may be requested by NCC



All SAEs, whether related or not related to study procedures, and AEs of special interest, must be collected from the time of enrollment through the end of study for that participant

# Unanticipated Problems

## Unanticipated Problems (UPs) vs. AEs:

- An unanticipated problem is unexpected, whereas an adverse event may be either expected or unexpected. Unanticipated problems may or may not be adverse events. Adverse events relate to harm to participants; unanticipated problems may involve an increased risk of harm even if no actual harm occurred.

## Reporting of UPs:

- The investigator will report any unanticipated problems and unanticipated adverse device effect to the reviewing IRB (Advarra), sponsor (Project Managers) and the contact PI (Dr. Khatri).
- Report within 10 working days from site awareness.

## Examples of UPs:

- A breach in confidentiality resulting from disclosure of confidential information that may involve risk to the subjects or others.
- Complaint of a participant or family member that indicates an unanticipated risk.
- Harm or risk of harm to research staff.
- Laboratory or medication errors that may involve potential risk to the individual or others.
- Any deviation from the IRB-approved protocol that increases risk or affects the participants' rights, safety, or welfare.

# Protocol Deviations

## Definition:

- Any noncompliance with the clinical study protocol, International Conference on ICH GCP, or MOP requirements. The noncompliance may be either on the part of the participant, the investigator, or the study site staff. As a result of deviations, corrective actions are to be developed by the site and implemented promptly.

## Responsibilities:

- It is the responsibility of the site investigator to use continuous vigilance to identify and report deviations that involve risk to participants or others.
  - Report within 10 working days of identification of the protocol deviation, or within 10 working days of the scheduled protocol-required activity.

## Examples:

- Enrolling a participant who did not meet all the inclusion/exclusion criteria.
- Failing to obtain or document informed consent prior to initiation of study procedures.
- Conducting a study visit outside of the required timeframe.
- Failing to report unanticipated problems involving risks to participants or others to the IRB and sponsor.



# Protocol Deviation- Poll Question

## Question:

Study visit 6 was completed via telephone. Which of the following assessments would be considered a protocol deviation if completed in this format?

- A) Rehab Utilization Assessment
- B) Geriatric Depression Scale
- C) MoCA
- D) NeuroQOL Anxiety (8Q)

# Informed Consent Overview

# WebDCU™ CTMS Training

- WebDCU Training: <https://dcu.musc.edu/campus/>
  - General Overview
  - Data Training
  - Regulatory Management
  - Delegation of Authority Log



# Obtaining Informed Consent

- Use the most current cIRB approved version of the ICF when obtaining consent
  - Your eConsent will always be the most recent version of the approved ICF.
  - All approved versions must be uploaded into WebDCU™ immediately upon receipt from the NCC.
  - eConsent will be updated by NCC accordingly.
- Consent should be obtained **ONLY** by staff who have been delegated this responsibility on the DOA
- eConsent will ensure that all sections have been correctly signed/dated by subject/person obtaining consent.
- Subject must personally sign the econsent. No LAR allowed



# Remote Monitoring of Informed Consents

- eConsents will be uploaded by sites as PDFs into WebDCU™ and remotely monitored by the NDMC team.

CRF	Baseline / Randomization 17-Mar-2017 Delete Visit
F102 Randomization	
F101 Inclusion and Exclusion Criteria	
F110 Imaging	
F501 Imaging - Central Reader	
F508 Imaging Volumes - Central Reader	
F502 Pre-ERCP BioSample Collection Log	
F509 Post-ERCP BioSample Collection Log	
F513 Numeric Pain Scale	
F514 ERCP	
F515 Subject Follow-Up Contact Log	
F245 Informed Consent Form Version 4	



# Common DCRs/queries on Informed Consents

- Do utilize consent process checklist to confirm the consent process is being followed
- eConsents uploaded to WebDCU should not be redacted & all pages should be included in the uploaded PDF packet
- Person obtaining consent was not designated to do so on the site DOA
- Do generate a Note-To-File explaining consent errors, immediate response, and corrective action and upload with the consent form



# THANK YOU!

## Questions?



# Closing Remarks



Extra Slides

# Staff Roles at Each Clinical Site

## PREMISES FOR STUDY STAFFING:

1. Strongly preferred that FM and ARAT are performed by PT/OT
2. The study requires that FM at Study Visit 2 & 6 is performed by same person
3. Neither TMS operator nor TMS assistant should do 90-day FM or ARAT
4. Site PIs may not have daily availability at many sites
5. Individual variations to recommended model may be needed

## STAFF MEMBERS TO BE TRAINED AND CERTIFIED AT SITES:

1. Site PI
2. 1<sup>0</sup> SC
3. 1<sup>0</sup> PT/OT
4. At least one additional staff member(s) and more encouraged
  - 2<sup>0</sup> SC or 2<sup>0</sup> PT/OT

Please Train **2 People** for Each Sets of Trainings:

(1) TMS (2) ARAT+FM, & (3) Other Behavioral Assessments

## RECOMMENDED VERIFY SITE TEAM MODEL

	Visit 1: Screening/Consent	Visit 2 & 3 (Inpatient)			Visit 4: Post-TMS Hospital Assessment (DC Day or D5 Post-TMS, whichever is Sooner)	Visit 5: Post-hospitalization Phone Follow Up (30d)	Visit 6 (90d) (Outpatient)	
		Baseline Clinical Assessments and MRI Facilitation (except FM)	FM	TMS Operator (TMS-trained)			TMS Assistant (no training)	FM and ARAT
1 <sup>0</sup> SC	X	X		X		X		X
1 <sup>0</sup> PT/OT			X				X	
2 <sup>0</sup> SC or 2 <sup>0</sup> PT/OT					X			
Site PI	Supervisory, may serve PT/OT or TMS role in some sites, or be available for backup in other sites							



# Staff Roles at Each Clinical Site

## **PREMISES FOR STUDY STAFFING:**

1. Strongly preferred that FM and ARAT are performed by PT/OT
2. The study requires that FM at Study Visit 2 & 6 is performed by same person
3. Neither TMS operator nor TMS assistant should do 90-day FM or ARAT
4. Site PIs may not have daily availability at many sites
5. Individual variations to recommended model may be needed

# Staff Roles at Each Clinical Site

## **STAFF MEMBERS TO BE TRAINED AND CERTIFIED AT SITES:**

1. Site PI
2. 1<sup>0</sup> SC
3. 1<sup>0</sup> PT/OT
4. At least one additional staff member(s) and more encouraged
  - 2<sup>0</sup> SC or 2<sup>0</sup> PT/OT

Please Train **2 People** for Each Sets of Trainings:

(1) TMS (2) ARAT+FM, & (3) Other Behavioral Assessments

# Staff Roles at Each Clinical Site

## RECOMMENDED VERIFY SITE TEAM MODEL

	Visit 1: Screening/Consent	Visit 2 & 3 (Inpatient)			Visit 4: Post-TMS Hospital Assessment (DC Day or D5 Post-TMS, whichever is Sooner)	Visit 5: Post-hospitalization Phone Follow Up (30d)	Visit 6 (90d) (Outpatient)		
		Baseline Clinical Assessments and MRI Facilitation (except FM)	FM	TMS Operator (TMS-trained)			TMS Assistant (no training)	FM and ARAT	Rest of Behavioral Assessments
1 <sup>0</sup> SC	X	X		X	X	X		X	
1 <sup>0</sup> PT/OT			X				X		
2 <sup>0</sup> SC or 2 <sup>0</sup> PT/OT					X				
Site PI	Supervisory, may serve PT/OT or TMS role in some sites, or be available for backup in other sites								

